NRXP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NR

Mkt Cap

$112.4M

Volume

1.19M

Next Earnings

November 13th

Loading chart

NR

NRXPNRX Pharmaceuticals, Inc. Common Stock

NRXP

Pay with—

Available Balance0.00

NR

Mkt Cap

$112.6M

Volume

1.19M

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

NRx Pharmaceuticals to Participate in Upcoming Investor ConferencesNRx Pharmaceuticals announced that its management team, led by CEO Jonathan Javitt, will participate in three investor conferences in September 2026: Moody Capital Solutions Disruptive Growth & Life Sciences Conference (Sept 9), Cantor Global Healthcare Conference (Sept 11), and H.C. Wainwright 28th Annual Global Investment Conference (Sept 14). The company is a clinical-stage biopharmaceutical firm developing NMDA platform therapeutics for CNS disorders including suicidal depression, chronic pain, and PTSD.GlobeNewswire Inc. · Sep 8, 2026

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockNRx Pharmaceuticals announced the pricing of an underwritten public offering of 5.7 million shares at $3.50 per share, expected to raise approximately $20 million (or $23 million with full underwriter option). The clinical-stage biopharmaceutical company plans to use net proceeds for working capital and general corporate purposes. The offering is expected to close on June 4, 2026.Benzinga · Jun 3, 2026

NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's WhyNRx Pharmaceuticals announced a proposed underwritten public offering of common stock, causing shares to plummet 19.05% to $3.74 in after-hours trading on Tuesday. The clinical-stage biopharmaceutical company, which develops treatments for CNS disorders including suicidal depression and PTSD, plans to use the net proceeds for working capital and general corporate purposes. BTIG LLC is acting as lead bookrunner for the offering.Benzinga · Jun 3, 2026

My Top 3 Biotech Stocks for May 2026With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.The Motley Fool · May 20, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateNRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-assisted TMS. The company also won a bid to acquire Geneuro's HERV-targeting asset portfolio and expanded its HOPE Therapeutics clinic network to five locations.GlobeNewswire Inc. · May 18, 2026

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateNRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in development. NRX-100 has received Fast Track Designation and NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.GlobeNewswire Inc. · May 14, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial OfficerNRx Pharmaceuticals announced the appointment of Glenn Tyson as its first Chief Commercial Officer. Tyson brings 25 years of pharmaceutical industry experience and clinical background in mental health treatment. The appointment comes as NRx anticipates FDA approval of its preservative-free ketamine ANDA and prepares to submit a New Drug Application to expand ketamine labeling for depression and suicidality treatment.GlobeNewswire Inc. · Apr 13, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine ApplicationNRx Pharmaceuticals received FDA preliminary alignment on labeling for its preservative-free ketamine generic drug application, with only minor formatting changes required. The company expects final approval under GDUFA in Summer 2026. The product addresses ketamine supply shortages and is manufactured in the US, aligning with FDA's focus on re-shoring critical drug supply elements.GlobeNewswire Inc. · Apr 6, 2026

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026NRx Pharmaceuticals announced it will host a conference call on March 24, 2026 to report full year 2025 financial results and provide updates on its drug development programs. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) for treating suicidal depression, chronic pain, and PTSD. NRX-100 has received Fast Track Designation and NRX-101 has been awarded Breakthrough Therapy Designation.GlobeNewswire Inc. · Mar 19, 2026

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSDHOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, announced the opening of a Palm Beach, FL clinic offering interventional psychiatry treatments including ketamine, transcranial magnetic stimulation (TMS), and hyperbaric oxygen therapy for depression and PTSD. Published results show 87% clinical response rates with their treatment protocol, and 90% return to full function when hyperbaric oxygen is added.GlobeNewswire Inc. · Mar 9, 2026

to start trading

NR

NRXPNRX Pharmaceuticals, Inc. Common Stock

NRXP

Pay with—

Available Balance0.00

Your PositionYou don't own any NRXP yet.

Related Tickers

Earnings